Health · Medical Research · 1 hr ago
Russian cancer vaccine shows early result in first patient
A Russian team has reported an early result from its personalized mRNA cancer vaccine.
The vaccine, called NeoOnkovak, was first tested in April on a patient diagnosed with skin melanoma.
The team’s scientific adviser said the patient’s metastases are no longer detectable and the patient has been well for four months.
The vaccine is made separately for each patient using genetic information from their tumor, rather than following one standard formula.
The patient remains under regular medical checks, planned to continue for three years.
One patient’s result does not prove the vaccine works, and specialists say larger clinical studies and longer testing are needed.
Separately, the European Commission approved Daraxonrasib for adults with metastatic pancreatic cancer who have already received at least one treatment.
Russia’s NeoOnkovak cancer vaccine has produced an early encouraging result in its first patient, according to a project adviser.
The patient, diagnosed with skin melanoma, has no detectable metastases, and has been in good health for four months.
The mRNA vaccine is made individually using genetic data from each patient’s tumour.
Doctors plan to monitor the patient for three years.
Experts say more clinical data and longer testing are needed to establish whether the treatment is effective.
- Who
- The first patient treated with NeoOnkovak, who was diagnosed with skin melanoma.
- What
- The patient’s metastases are no longer detectable, according to Alexander Gintsburg.
- When
- The vaccine was first clinically tested in the patient in April. The article was published on November 19, 2026.
- Where
- Russia.
- Why
- The vaccine is designed to prompt the immune system to recognise and destroy cancer cells.
This story does not have two clearly opposing sides.
NeoOnkovak was clinically tested for the first time in a patient diagnosed with skin melanoma.
Gintsburg said the patient was in good health and metastases were no longer detectable.
Doctors plan to continue monitoring the patient.
- Vaccine
- NeoOnkovak
- Technology
- mRNA
- First patient
- Diagnosed with skin melanoma
- Reported result
- Metastases no longer detectable
- Planned monitoring
- Three years
- Project centres
- Gamaleya National Research Center for Epidemiology and Microbiology and the National Radiology Research Center